Bristol-Myers Squibb Company (BMY), Johnson & Johnson (JNJ) Ink Hepatitis C Pact  
12/5/2011 7:06:11 AM

Bristol-Myers Squibb Co. said Friday it will collaborate with a unit of Johnson & Johnson to study a potential combination therapy for chronic hepatitis C. The companies will study a regimen that combines Johnson & Johnson's drug TMC435 with Bristol-Myers Squibb's daclatasvir. The clinical trial of the drug cocktail will begin in the first half of 2012. It will include a combination of the two drugs, the drugs plus pegylated interferon and ribavirin, and the drugs plus ribavirin. Pegylated interferon and ribavirin have been staples of hepatitis C treatment for decades.